Company Announcement / Press release Archives - Page 14 of 19

Invitation to virtual Capital Markets Day with Xspray on June 25 at 14.00-15.30 CET

Xspray Pharma (Nasdaq Stockholm: XSPRAY) will host a virtual Capital Market Day on June 25 at 14.00-15.30 CET. Theme of the day will be how Xspray's product candidate HyNap-Dasa can pave the way for a number of followers based on the company's technology platform. The Capital Markets Day can be seen via Xspray's website: www.xspraypharma.com. […]

Xspray Pharma initiates pivotal registration studies with HyNap-Dasa for the market approval application in the United States

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces the start of the pivotal clinical bioequivalence studies with HyNap-Dasa. The studies are conducted on healthy volunteers with the objective to demonstrate that HyNap-Dasa is bioequivalent to the original drug Sprycel® (dasatinib). The bioequivalence studies consist of two studies, where the first one, starting today, is conducted […]

Bulletin from the annual general meeting of Xspray Pharma AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Xspray Pharma AB (publ) (“Xspray”) on 14 May 2020 in Stockholm. Adoption of income statement and balance sheet for the financial year 2019 and discharge from liability The AGM resolved to adopt the income statement for the financial year 2019 as well […]

Xspray Pharma publishes Interim report Q1, January – March 2020

“This year is an important year for Xspray. I expect that the amorphous material provided by our unique production facility will provide positive clinical data, which is a prerequisite for us to apply for market approval for HyNap-Dasa in the U.S. This means that we together with a partner who either buys or licenses the […]

Xspray Pharma provides an update on how the Covid-19 pandemic affects the company’s planned clinical studies

STOCKHOLM – April 15, 2020. Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces that the start of the pivotal clinical bioequivalence studies with HyNap-Dasa are expected to be postponed by two to three months due to the Covid-19 pandemic. Xspray Pharma's planned clinical trials are, like the trials of many other drug developing companies, affected by […]

XSpray: Notice of annual general meeting of Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, are summoned to the annual general meeting on Thursday 14 May 2020 at 11.00 CEST at Advokatfirman Vinge's office on Stureplan 8 in Stockholm. Registration starts at 10.30 CEST. Due to the current pandemic (covid-19), Xspray has taken a number of precautionary measures ahead of […]

Trading in Xspray Pharma’s shares commences today on Nasdaq Stockholm

STOCKHOLM – March 27, 2020. Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today the commencement of trading in the company’s shares on Nasdaq Stockholm's main market. “We are very excited about the move to the main market. This is a natural step as we approach a new phase in the company's development and move towards commercialization of […]

Bulletin from the extraordinary general meeting of Xspray Pharma AB (publ)

Press release, Solna on 26 March 2020 The following resolution was passed at the extraordinary general meeting in Xspray Pharma AB (publ) today, on 26 March 2020. Adoption of incentive programme The extraordinary general meeting resolved, in accordance with the board’s proposal, to adopt a long-term incentive programme for a number of employees of Xspray. According […]

The conditions for Xspray Pharma’s listing on Nasdaq Stockholm have been fulfilled

STOCKHOLM – March 26, 2020. Xspray Pharma AB (Nasdaq First North Growth Market: XSPRAY) announced on March 18, 2020, that the company had received clearance for a listing on Nasdaq Stockholm, following the fulfilment of customary conditions. Xspray Pharma has today received information that the conditions have been fulfilled and accordingly, Xspray Pharma’s first day of trading on […]

Xspray Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

STOCKHOLM – March 23, 2020. Xspray Pharma AB (Nasdaq First North Growth Market: XSPRAY) announced on March 18, 2020 that Nasdaq Stockholm’s listing committee had approved that the company’s shares are admitted to trading on Nasdaq Stockholm’s main market. Today, on 23 March, the prospectus that has been prepared by the company in connection with the listing was […]